Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Aug 2020
Multicenter StudyPhase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Tepotinib (MSC2156119J) is an oral, potent and highly selective small molecule mesenchymal-epithelial transition factor (MET) inhibitor for which the recommended Phase II dose of 500 mg once daily has been defined, based on the first-in-man trial conducted in the USA and Europe. We carried out a multicenter Phase I trial with a classic `3 + 3' design to determine the recommended Phase II dose in Japanese patients with solid tumors (NCT01832506). ⋯ These results, including initial signals of antitumor activity, support further development of tepotinib in Japanese patients with cancer.